Gynecologic oncologists currently lack risk models that can accurately predict an endometrial cancer diagnosis at the time of hysterectomy for endometrial intraepithelial neoplasia. To fill this gap,...
The study findings potentially challenge the conventional wisdom that the risk of Richter transformation would increase as patients with chronic lymphocytic leukemia live longer with novel treatments. This...
Researchers developed a retrospective cohort study to examine the reoperation rates and health care costs associated with reoperation for patients who underwent breast-conserving surgery.
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
Using data from observational and clinical trials, researchers examined the association between advancements in metastatic breast cancer treatment and the observed improvement in breast cancer mortality...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
A recent phase 3 trial showed that for untreated patients with chronic lymphocytic leukemia, measurable residual disease-directed ibrutinib–venetoclax therapy had superior progression-free survival compared...
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
In a single-group trial, researchers assessed the safety and risks associated with interrupting endocrine therapy for women with stage I, II, or III breast cancer attempting pregnancy.
